Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2017

01-12-2017 | Epidemiology

Breast cancer screening in transgender patients: findings from the 2014 BRFSS survey

Authors: Anand Narayan, Lizza Lebron-Zapata, Elizabeth Morris

Published in: Breast Cancer Research and Treatment | Issue 3/2017

Login to get access

Abstract

Purpose

Transgender patients undergoing transitions often receive cross-sex hormonal therapies, placing them at uncertain risk for developing breast cancer. There is limited population-based information about the extent to which transgender patients undergo mammography screening. Our purpose was to determine the extent to which transgender patients undergo mammography screening using nationally representative survey data.

Methods

Transgender participants between ages 40–74 in the 2014 Behavioral Risk Factor Surveillance System survey were included. Proportions undergoing mammography screening in the last year or two years were calculated stratified by age category and transition status [male to female(MtF), female to male(FtM), non-conforming]. For each transition status, predictors of mammography screening were calculated using logistic regression.

Results

220 transgender patients were within 40–74 years old(35% were MtF, 51% were FtM, 14% were non-conforming). 60.0% underwent mammography screening within the last year (MtF—54.5%, FtM—64.3%, non-conforming—58.1%). 74.1% underwent screening within the last two years(MtF—70.1%, FtM—75.9%, non-conforming—77.4%). For all transgender patients, income category (OR 1.16, 0.82–1.64), higher education category (OR 1.09, 0.31–3.86) and health insurance (OR 0.38, 0.10–1.41) were not associated with increased adherence to mammography screening. Transgender patients were comparably likely to undergo mammography screening compared with non-transgender patients (Adjusted OR 0.97, 0.58–1.62).

Conclusions

High proportions of transgender survey respondents undergo mammography screening (57.9–66.1% within the last year, 71.9–74.4% within the last two years) in our sample, proportions comparable to non-transgender survey respondents.
Literature
1.
go back to reference Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System Survey Data. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2014 Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System Survey Data. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2014
2.
go back to reference Deutsch MB, Buchholz D (2015) Electronic health records and transgender patients—practical recommendations for the collection of gender identity data. J Gen Intern Med 30(6):843–847CrossRefPubMedPubMedCentral Deutsch MB, Buchholz D (2015) Electronic health records and transgender patients—practical recommendations for the collection of gender identity data. J Gen Intern Med 30(6):843–847CrossRefPubMedPubMedCentral
3.
go back to reference Bazzi AR, Whorms DS, King DS, Potter J (2015) Adherence to mammography screening guidelines among transgender persons and sexual minority women. Am J Public Health. 105(11):2356–2358CrossRefPubMedPubMedCentral Bazzi AR, Whorms DS, King DS, Potter J (2015) Adherence to mammography screening guidelines among transgender persons and sexual minority women. Am J Public Health. 105(11):2356–2358CrossRefPubMedPubMedCentral
4.
go back to reference McPhee SJ, Nguyen TT, Shema SJ et al (2002) Validation of recall of breast and cervical cancer screening by women in an ethnically diverse population. Prev Med 35:463–473CrossRefPubMed McPhee SJ, Nguyen TT, Shema SJ et al (2002) Validation of recall of breast and cervical cancer screening by women in an ethnically diverse population. Prev Med 35:463–473CrossRefPubMed
5.
go back to reference Grant JM, Mottet LA, Tanis J, Harrison J, Herman JL, Keisling M (2011) Injustice at every turn: a report of the national transgender discrimination survey. National Center for Transgender Equality and National Gay and Lesbian Task force, Washington, DC Grant JM, Mottet LA, Tanis J, Harrison J, Herman JL, Keisling M (2011) Injustice at every turn: a report of the national transgender discrimination survey. National Center for Transgender Equality and National Gay and Lesbian Task force, Washington, DC
6.
go back to reference Hubbard RA, O’Meara ES, Henderson LM et al (2016) Multilevel factors associated with long-term adherence to screening mammography in older women in the U.S. Prev Med 89:169–177CrossRefPubMedPubMedCentral Hubbard RA, O’Meara ES, Henderson LM et al (2016) Multilevel factors associated with long-term adherence to screening mammography in older women in the U.S. Prev Med 89:169–177CrossRefPubMedPubMedCentral
7.
go back to reference Selvin E, Brett KM (2003) Breast and cervical cancer screening: sociodemographic predictors among white, black, and hispanic women. Am J Public Health 93(4):618–623CrossRefPubMedPubMedCentral Selvin E, Brett KM (2003) Breast and cervical cancer screening: sociodemographic predictors among white, black, and hispanic women. Am J Public Health 93(4):618–623CrossRefPubMedPubMedCentral
10.
go back to reference Collaborative Group on Hormonal Factors in Breast Cancer (2012) Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118,964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 13(11):1141–1151CrossRefPubMedCentral Collaborative Group on Hormonal Factors in Breast Cancer (2012) Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118,964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 13(11):1141–1151CrossRefPubMedCentral
11.
go back to reference Rossouw JE, Anderson GL, Prentice RL et al (2002) Writing Group for the women’s health initiative investigators. risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRefPubMed Rossouw JE, Anderson GL, Prentice RL et al (2002) Writing Group for the women’s health initiative investigators. risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRefPubMed
12.
go back to reference Chlebowski RT, Rohan TE, Manson JE et al (2015) Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 women’s health initiative randomized clinical trials. JAMA Oncol. 1(3):296–305CrossRefPubMed Chlebowski RT, Rohan TE, Manson JE et al (2015) Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 women’s health initiative randomized clinical trials. JAMA Oncol. 1(3):296–305CrossRefPubMed
13.
go back to reference Gooren LJ, van Trotsenburg MA, Giltay EJ, van Diest PJ (2013) Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med. 10(12):3129–3134CrossRefPubMed Gooren LJ, van Trotsenburg MA, Giltay EJ, van Diest PJ (2013) Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med. 10(12):3129–3134CrossRefPubMed
14.
go back to reference Brown GR, Jones KT (2015) Incidence of breast cancer in a cohort of 5,135 transgender veterans. Breast Cancer Res Treat 149(1):191–198CrossRefPubMed Brown GR, Jones KT (2015) Incidence of breast cancer in a cohort of 5,135 transgender veterans. Breast Cancer Res Treat 149(1):191–198CrossRefPubMed
15.
go back to reference Makadon HJ, Mayer KH, Potter J, Goldhammer H (2015) Fenway guide to lesbian, gay, bisexual and transgender health, 2nd edn. American College of Physicians, Philadelphia Makadon HJ, Mayer KH, Potter J, Goldhammer H (2015) Fenway guide to lesbian, gay, bisexual and transgender health, 2nd edn. American College of Physicians, Philadelphia
16.
go back to reference Rebbeck TR, Friebel T, Lynch HT et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22(6):1055–1062CrossRefPubMed Rebbeck TR, Friebel T, Lynch HT et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22(6):1055–1062CrossRefPubMed
Metadata
Title
Breast cancer screening in transgender patients: findings from the 2014 BRFSS survey
Authors
Anand Narayan
Lizza Lebron-Zapata
Elizabeth Morris
Publication date
01-12-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4461-8

Other articles of this Issue 3/2017

Breast Cancer Research and Treatment 3/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine